



Short version of press release from Emotra AB (publ)
Gothenburg October 8, 2013

Emotra invitation to investment meeting on November 12, 2013

- *Emotra's method, EDOR, for evaluation of suicide risk, generates interest*
 - *The company's top priority is to perform broad clinical evaluations in Europe*
 - *Shareholders and investors are hereby invited to come and listen to information about the company's activities*
-

Emotra is happy to invite shareholders and investors to a short information meeting at Radisson Blu Royal Viking hotel in Stockholm, on November 12, at 16.30 – 19.00.

After serving coffee and sandwich the information meeting will start at 17.00. when the company will present its activities. After the information there will be time for questions.

Program

- Emotra's research manager, associate professor at the Linköping university , Lars-Håkan Thorell, the inventor of EDOR, will inform about his method, the research, that has demonstrated the high accuracy of the method and how it is intended to be used.
- Emotra's CEO and president, Claes Holmberg, will tell about the strategies and future plans
- Time for questions

The information will be presented in Swedish.

In order to simplify the planning of the meeting we kindly ask everyone who want to participate, to mail Claes Holmberg, not later than November 7 at the address claes@emotra.se

It is enough to inform us about the names and mail addresses to all the participants you will bring to the meeting.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB (publ), Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se